Associated Papers
Moving Beyond Somatic Alterations: Uncovering the Germline Basis of Myeloid Malignancies.
Elbaz Younes I et al.
Cancers, 2026
Impact of CHEK2 germline variants on haematological malignancy risk and outcomes of allogeneic HSCT.
Lahtinen AK et al.
British Journal of Haematology, 2025
Clinicopathological and prognostic significance of DDX41 mutation in myeloid neoplasms: a systematic review and meta-analysis.
Miao L et al.
Annals of Hematology, 2025
ATM-dependent DNA damage response constrains cell growth and drives clonal hematopoiesis in telomere biology disorders.
Sande CM et al.
The Journal of Clinical Investigation, 2025
Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndrome.
Kusne Y et al.
British Journal of Haematology, 2025
Germline DDX41 mutations in myeloid neoplasms: the current clinical and molecular understanding.
Kida J et al.
Current Opinion in Hematology, 2025
Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohorts.
Hendricks RM et al.
Leukemia, 2025
Molecular taxonomy of myelodysplastic syndromes and its clinical implications.
Bernard E et al.
Blood, 2024
DDX41: exploring the roles of a versatile helicase.
Winstone L et al.
Biochemical Society Transactions, 2024
Multifunctional role of DEAD-box helicase 41 in innate immunity, hematopoiesis and disease.
Ma J et al.
Frontiers in Immunology, 2024
Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms.
Badar T et al.
Haematologica, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
Bataller A et al.
American Journal of Hematology, 2023
Identification of DHX40 as a candidate susceptibility gene for colorectal and hematological neoplasia.
Olkinuora A et al.
Leukemia, 2023
Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity.
Molteni E et al.
Blood, 2023
DDX41 mutations in patients with non-myeloid hematologic neoplasms.
Jelloul FZ et al.
American Journal of Hematology, 2023
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
Nannya Y et al.
Blood Advances, 2023
Case Report of a Myeloid Neoplasm with Pathogenic Germline Variant in DDX41 and Constitutional inv(7)(q11.2q22) Along With JAK2 Pathogenic Variant in a 9-Year-old Patient Who Presented With Features of Essential Thrombocythemia.
Gray AL et al.
Journal of Pediatric Hematology/oncology, 2023
Increased clonal hematopoiesis involving DNA damage response genes in patients undergoing lung transplantation.
Tague LK et al.
Jci Insight, 2023
Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma.
Nair NU et al.
Cell Reports. Medicine, 2023
Germ line DDX41 mutations define a unique subtype of myeloid neoplasms.
Makishima H et al.
Blood, 2023
Current Understanding of DDX41 Mutations in Myeloid Neoplasms.
Kim K et al.
Cancers, 2023
Clinically relevant germline variants in allogeneic hematopoietic stem cell transplant recipients.
Lahtinen AK et al.
Bone Marrow Transplantation, 2023
Biallelic disruption of DDX41 activity is associated with distinct genomic and immunophenotypic hallmarks in acute leukemia.
Tierens A et al.
Frontiers in Oncology, 2023
Pediatric Germline Predisposition to Myeloid Neoplasms.
Thompson C et al.
Current Hematologic Malignancy Reports, 2022
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms.
Badar T et al.
Current Hematologic Malignancy Reports, 2022
Acquired somatic variants in inherited myeloid malignancies.
Armes H et al.
Leukemia, 2022
A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report.
Shin WY et al.
Bmc Medical Genomics, 2022
AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome.
Li P et al.
Leukemia, 2022
Unique ethnic features of DDX41 mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia.
Choi EJ et al.
Haematologica, 2022
Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms.
Alkhateeb HB et al.
Blood Advances, 2022
Unique role of DDX41, a DEAD-box type RNA helicase, in hematopoiesis and leukemogenesis.
Shinriki S et al.
Frontiers in Oncology, 2022
Molecular Pathogenesis in Myeloid Neoplasms with Germline Predisposition.
Gao J et al.
Life (basel, Switzerland), 2021
Clinical and Pathologic Spectrum of DDX41-Mutated Hematolymphoid Neoplasms.
Goyal T et al.
American Journal of Clinical Pathology, 2021
Next-generation sequencing reveals the presence of DDX41 mutations in acute lymphoblastic leukemia and aplastic anemia.
Zhang Y et al.
Ejhaem, 2021
Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations.
Qu S et al.
British Journal of Haematology, 2021
Clinical features of DDX41 mutation-related diseases: a systematic review with individual patient data.
Wan Z et al.
Therapeutic Advances in Hematology, 2021
[Lenalidomide for myelodysplastic syndrome with excess blasts with germline DDX41 mutation: a case report and literatures review].
Chen J et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 2020
Rare germline variant contributions to myeloid malignancy susceptibility.
Li ST et al.
Leukemia, 2020
Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation.
Abou Dalle I et al.
American Journal of Hematology, 2020
Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis.
Brown AL et al.
Leukemia & Lymphoma, 2020
Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations.
Bannon SA et al.
Frontiers in Oncology, 2020
Germline DDX41 mutations define a significant entity within adult MDS/AML patients.
Sébert M et al.
Blood, 2019
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.
Quesada AE et al.
American Journal of Hematology, 2019
Myeloid neoplasms with germline DDX41 mutation.
Cheah JJC et al.
International Journal of Hematology, 2017